CD59 and bone metastasis: According to the molecular imaging TNM (miTNM) definition [30,31], the distribution of the suspected PCa localizations in a per lesion analysis was as follows: prostate bed (miTr) in 7.7% of cases (34/440); pelvic nodes (miN1) in 21.8% (96/440); extra-pelvic nodes (miM1a) in 6.8% (30/440); bone metastasis (miM1b) in 10.7% (47/440); and visceral non-nodal metastasis (miM1c) in 2.3% (10/440).